JP2000517295A - マラリア用ワクチン組成物 - Google Patents

マラリア用ワクチン組成物

Info

Publication number
JP2000517295A
JP2000517295A JP10507631A JP50763198A JP2000517295A JP 2000517295 A JP2000517295 A JP 2000517295A JP 10507631 A JP10507631 A JP 10507631A JP 50763198 A JP50763198 A JP 50763198A JP 2000517295 A JP2000517295 A JP 2000517295A
Authority
JP
Japan
Prior art keywords
protein
vaccine
malaria
vaccine composition
homology
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP10507631A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000517295A5 (id
Inventor
コーエン，ジョゼフ
Original Assignee
スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） filed Critical スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム）
Publication of JP2000517295A publication Critical patent/JP2000517295A/ja
Publication of JP2000517295A5 publication Critical patent/JP2000517295A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP10507631A 1996-08-02 1997-07-31 マラリア用ワクチン組成物 Pending JP2000517295A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9616351.4A GB9616351D0 (en) 1996-08-02 1996-08-02 Vaccine composition
GB9616351.4 1996-08-02
PCT/EP1997/004326 WO1998005355A1 (en) 1996-08-02 1997-07-31 Vaccine composition against malaria

Publications (2)

Publication Number Publication Date
JP2000517295A true JP2000517295A (ja) 2000-12-26
JP2000517295A5 JP2000517295A5 (id) 2005-04-07

Family

ID=10797980

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10507631A Pending JP2000517295A (ja) 1996-08-02 1997-07-31 マラリア用ワクチン組成物

Country Status (32)

Country Link
US (2) US20020172692A1 (id)
EP (2) EP1623720A3 (id)
JP (1) JP2000517295A (id)
KR (1) KR20000029747A (id)
CN (1) CN1241639C (id)
AP (1) AP1166A (id)
AR (1) AR008799A1 (id)
AT (1) ATE394119T1 (id)
AU (1) AU706303B2 (id)
BG (1) BG63290B1 (id)
BR (1) BR9710913A (id)
CA (1) CA2262402A1 (id)
CO (1) CO4650186A1 (id)
CZ (1) CZ290826B6 (id)
DE (1) DE69738672D1 (id)
DZ (1) DZ2283A1 (id)
EA (1) EA002167B1 (id)
GB (1) GB9616351D0 (id)
ID (1) ID17860A (id)
IL (1) IL128318A (id)
MA (1) MA24291A1 (id)
MY (1) MY116128A (id)
NO (1) NO319844B1 (id)
OA (1) OA10969A (id)
PE (1) PE97298A1 (id)
PL (1) PL188741B1 (id)
SK (1) SK282438B6 (id)
TR (1) TR199900195T2 (id)
UA (1) UA68336C2 (id)
UY (1) UY24654A1 (id)
WO (1) WO1998005355A1 (id)
ZA (1) ZA976815B (id)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008544969A (ja) * 2005-06-30 2008-12-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 抗マラリアワクチン
JP2009543846A (ja) * 2006-07-18 2009-12-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム マラリア用ワクチン
JP2011507816A (ja) * 2007-12-21 2011-03-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム マラリア用ワクチン

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915204D0 (en) * 1999-06-29 1999-09-01 Smithkline Beecham Biolog Vaccine
CA2502268A1 (en) 2002-10-23 2004-05-06 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
ATE458747T1 (de) * 2003-12-01 2010-03-15 Meiji Dairies Corp Angiontensin converting enzyme hemmendes peptid
ATE526036T1 (de) * 2005-08-02 2011-10-15 Novartis Vaccines & Diagnostic Reduzierung der interferenz zwischen ölhaltigen adjuvanzien und surfactanthaltigen antigenen
GB0614254D0 (en) * 2006-07-18 2006-08-30 Smithkline Beecham Biolog Vaccine
US8945582B2 (en) 2006-09-07 2015-02-03 Glaxosmithkline Biologicals S.A. Vaccine
TR201802221T4 (tr) 2007-08-13 2018-03-21 Glaxosmithkline Biologicals Sa Aşılar.
AR069936A1 (es) 2007-12-24 2010-03-03 Glaxosmithkline Biolog Sa Vacunas contra la malaria que comprenden una proteina de fusion derivada de proteina cs de plasmodium vivax y un antigeno s de hepatitis b
EP2313108A4 (en) * 2008-06-30 2013-06-12 Us Army As Represented By The Secretary Of The Army MALARIA VACCINE FROM SELF-ORGANIZING POLYPEPTIDE NANOTEHICLES
EP2451478A4 (en) * 2009-11-05 2013-11-20 Us Navy PLASMODIUM FALCIPARUM SPOROZOITE AND LIVERPHASE ANTIGENS THEREWITH
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
CN104338129B (zh) * 2013-07-26 2017-05-24 中国科学院上海巴斯德研究所 雷帕霉素作为疫苗佐剂的用途及制备方法
BR112019011286A2 (pt) 2016-12-07 2019-10-15 Glaxosmithkline Biologicals S.A. métodos para produzir uma composição de lipossoma, para preparar uma composição de vacina e para preparar um kit de vacina.
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CA3063954A1 (en) 2017-05-30 2018-12-06 Glaxosmithline Biologicals S.A. Methods for manufacturing an adjuvant
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
JP7640473B2 (ja) 2019-06-05 2025-03-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0071705B1 (en) * 1981-05-21 1989-11-23 The Wellcome Foundation Limited Protozoal antigen
PT82282B (pt) * 1985-03-28 1988-02-17 Univ New York Processo de preparacao de um conjugado de proteina de suporte-antigeno imunogenico para uso como vacina contra malaria
GB8819209D0 (en) * 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
GB9012580D0 (en) * 1990-06-06 1990-07-25 Univ Nijmegen Novel protein
FR2679776A1 (fr) * 1991-07-31 1993-02-05 Pasteur Institut Melange de constituants peptidiques ayant des proprietes vaccinantes contre le paludisme, notamment du a plasmodium falciparum.
ATE177755T1 (de) * 1991-11-16 1999-04-15 Smithkline Beecham Biolog Hybrides protein zwischen cs aus plasmodium und hbsag
US6169171B1 (en) * 1992-02-27 2001-01-02 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBSAG
DK0671948T3 (da) * 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM368994A0 (en) * 1994-02-04 1994-02-24 Saramane Pty Ltd Malaria merozoite antigen subunit vaccine
FR2744724B1 (fr) * 1996-02-14 2002-08-02 Pasteur Institut Proteine recombinante contenant un fragment c-terminal de la proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques
FR2744723A1 (fr) * 1996-02-14 1997-08-14 Pasteur Institut Proteine recombinante contenant un fragment c-terminal d'une proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008544969A (ja) * 2005-06-30 2008-12-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 抗マラリアワクチン
JP2009543846A (ja) * 2006-07-18 2009-12-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム マラリア用ワクチン
JP2009543569A (ja) * 2006-07-18 2009-12-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム マラリア用ワクチン
JP2011507816A (ja) * 2007-12-21 2011-03-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム マラリア用ワクチン

Also Published As

Publication number Publication date
TR199900195T2 (xx) 1999-04-21
CN1241639C (zh) 2006-02-15
IL128318A (en) 2002-04-21
CN1231613A (zh) 1999-10-13
BR9710913A (pt) 1999-08-17
BG63290B1 (bg) 2001-09-28
WO1998005355A1 (en) 1998-02-12
US20060292170A1 (en) 2006-12-28
UA68336C2 (en) 2004-08-16
CO4650186A1 (es) 1998-09-03
NO990464L (no) 1999-02-01
ID17860A (id) 1998-01-29
EP1623720A3 (en) 2006-02-22
EP0957933A1 (en) 1999-11-24
EA199900069A1 (ru) 1999-10-28
OA10969A (en) 2003-03-04
EP1623720A2 (en) 2006-02-08
PL188741B1 (pl) 2005-04-29
ATE394119T1 (de) 2008-05-15
UY24654A1 (es) 2001-08-27
SK282438B6 (sk) 2002-02-05
BG103141A (en) 1999-08-31
AP9901448A0 (en) 1999-03-31
CA2262402A1 (en) 1998-02-12
PE97298A1 (es) 1999-02-14
US20020172692A1 (en) 2002-11-21
CZ290826B6 (cs) 2002-10-16
DZ2283A1 (fr) 2002-12-25
MY116128A (en) 2003-11-28
PL331424A1 (en) 1999-07-19
AR008799A1 (es) 2000-02-23
DE69738672D1 (de) 2008-06-19
KR20000029747A (ko) 2000-05-25
MA24291A1 (fr) 1998-04-01
EA002167B1 (ru) 2002-02-28
AP1166A (en) 2003-06-30
NO990464D0 (no) 1999-02-01
AU706303B2 (en) 1999-06-10
GB9616351D0 (en) 1996-09-11
NO319844B1 (no) 2005-09-19
ZA976815B (en) 1998-05-11
EP0957933B1 (en) 2008-05-07
AU4204097A (en) 1998-02-25
CZ29299A3 (cs) 1999-06-16
SK11599A3 (en) 2000-03-13
IL128318A0 (en) 2000-01-31

Similar Documents

Publication Publication Date Title
JP2000517295A (ja) マラリア用ワクチン組成物
JP4126079B2 (ja) アジュバント組成物
JP5486802B2 (ja) 抗マラリアワクチン
KR101362097B1 (ko) 플라스모디움 항원을 포함하는 백신
TW200940086A (en) Vaccines for malaria
CA2376926A1 (en) Use of cpg as an adjuvant for malaria vaccine
US20040067236A1 (en) Immunogenic compositions comprising liver stage malarial antigens
US20030133944A1 (en) Vaccine composition against malaria
EP0241725B1 (en) Improvements in and relating to vaccines
US20080131464A1 (en) Vaccines
US20110262469A1 (en) Malaria vaccine based on fragments and combination of fragments of the cs protein of plasmodium vivax

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080513